A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Advanced or Metastatic Solid Tumor
Interventions: DRUG: rebastinib|DRUG: Paclitaxel
Sponsor: Deciphera Pharmaceuticals LLC